The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults
Open accessAbstract
BACKGROUND: A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. An analogous regimen using HIV-1 subtype C virus showed potent humoral and cellular responses in a phase 1-2a trial in South Africa. Efficacy data and additional safety data were needed for this regimen in a larger population in South Africa. METHODS: In this phase 2b-3 trial, we randomly assigned 5404 adults without HIV-1 infection to receive the vaccine (2704 participants) or placebo (2700 participants). The vaccine regimen consisted of injections of ALVAC-HIV at months 0 and 1, followed by four booster injections of ALVAC-HIV plus bivalent subtype C gp120-MF59 adjuvant at months 3, 6, 12, and 18. The primary efficacy outcome was the occurrence of HIV-1 infection from randomization to 24 months. RESULTS: In January 2020, prespecified criteria for nonefficacy were met at an interim analysis; further vaccinations were subsequently halted. The median age of the trial participants was 24 years; 70% of the participants were women. The incidence of adverse events was similar in the vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P = 0.84). CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Cited by
Delany-Moretlwe, S., Hughes, J. P., Bock, P., Ouma, S. G., Hunidzarira, P., Kalonji, D., Kayange, N., Makhema, J., Mandima, P., Mathew, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00538-4 · Cited by 586
Self-citationStrategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
The use of viral vectors in vaccine development
Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. (2022) · npj Vaccines · doi:10.1038/s41541-022-00503-y · Cited by 310
Shangguan, S., Ehrenberg, P. K., Geretz, A., Yum, L., Kundu, G., May, K., Fourati, S., Nganou-Makamdop, K., Williams, L. D., Sawant, S., et al. (2021) · eLife · doi:10.7554/elife.69577 · Cited by 26
Self-citation
Metadata
- Authors
- Gray, G. E., Bekker, L.-G., Laher, F., Malahleha, M., Allen, M., Moodie, Z., Grunenberg, N., Huang, Y., Grove, D., Prigmore, B., Kee, J. J., Benkeser, D., Hural, J., Innes, C., Lazarus, E., Meintjes, G., Naicker, N., Kalonji, D., Nchabeleng, M., Sebe, M., Singh, N., Kotze, P., Kassim, S., Dubula, T., Naicker, V., Brumskine, W., Ncayiya, C. N., Ward, A. M., Garrett, N., Kistnasami, G., Gaffoor, Z., Selepe, P., Makhoba, P. B., Mathebula, M. P., Mda, P., Adonis, T., Mapetla, K. S., Modibedi, B., Philip, T., Kobane, G., Bentley, C., Ramirez, S., Takuva, S., Jones, M., Sikhosana, M., Atujuna, M., Andrasik, M., Hejazi, N. S., Puren, A., Wiesner, L., Phogat, S., Diaz Granados, C., Koutsoukos, M., Van Der Meeren, O., Barnett, S. W., Kanesa-Thasan, N., Kublin, J. G., McElrath, M. J., Gilbert, P. B., Janes, H., & Corey, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-25
- Volume
- 384
- Issue
- 12
- Pages
- 1089-1100
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3137307641
- Cited by
- 230
- References
- 1
- FWCI
- 22.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.